# Isolation, characterization, therapeutic and prophylactic applications of a lytic bacteriophage to combat multi-drug resistance Shigella flexneri: an animal study model

**Authors:** Parisa Abbasi Fashami, Abazar Pournajaf, Nour Amirmozafari, Masoume Hallajzadeh, Vahid Pirhajati Mahabadi, Reza Saghiri, Soraya Khafri, Rezvan Golmoradi Zadeh, Sousan Akrami, Sajjad Asgharzadeh, Mehdi Rajabnia

PMC · DOI: 10.3205/dgkh000543 · GMS Hygiene and Infection Control · 2025-04-30

## TL;DR

This study explores using a bacteriophage to treat and prevent Shigella flexneri infections in mice, which could help combat drug resistance.

## Contribution

The study isolates and characterizes a lytic bacteriophage effective against multidrug-resistant Shigella flexneri in an animal model.

## Key findings

- The isolated bacteriophage belongs to the Myoviridae family and causes complete lysis of S. flexneri in vitro.
- Administering the phage before infection improves outcomes, while post-infection treatment has therapeutic effects in mice.
- The phage shows potential as a therapeutic option for multidrug-resistant bacillary dysentery.

## Abstract

Shigella (S.) flexneri is one of the most important causes of disease in children with diarrhea in Iran. Today, bacteriophages are an attractive option to resolve the drug resistance problem among pathogenic agents. Accordingly, the present study aimed to isolate a lytic bacteriophage of S. flexneri and investigate its impact on reducing excretion of Shigella in mouse models suffering from bacillary dysentery.

S. flexneri ATCC12022 was used. Identification of the phage isolated from hospital wastewater was performed using Transmission Electron Microscopy (TEM). Stability tests were performed to determine the sensitivity of isolated phages to various factors such as temperature, pH and bile salts. A male Syrian mouse model (C57), with mice 6 weeks of age weighing 22–25 g, was used to ensure safety and efficacy of the bacteriophage in reducing Shigella in stool. Treatment with the phage was performed (I) 1 h before, (II) 1 h after, (III) 5 h after, and (IV) 1 h before +1 h after bacterial challenge.

TEM indicated that the bacteriophage used in this study belongs to the Myoviridae family. Administration of one dose of bacteriophage before the infection can accelerate improvement post-transfection, and administration of bacteriophage post-infection has a therapeutic influence.

In vivo and in vitro results indicate that our bacteriophage causes complete lysis of S. flexneri. Thus, this phage could be a therapeutic option for treating bacillary dysentery resulting from multidrug-resistant S. flexneri.

## Linked entities

- **Species:** Shigella flexneri (taxon 623), Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** bacillary dysentery (MESH:D004405), infection (MESH:D007239), diarrhea (MESH:D003967)
- **Chemicals:** bile salts (MESH:D001647)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Myoviridae [taxon 10662], Bacteriophage sp. (species) [taxon 38018], Shigella (genus) [taxon 620], Shigella flexneri (species) [taxon 623]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12101133/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12101133/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12101133/full.md

---
Source: https://tomesphere.com/paper/PMC12101133